Chugai Pharmaceutical Co Ltd
F:CUP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Chugai Pharmaceutical Co Ltd
F:CUP
|
JP |
Intrinsic Value
The intrinsic value of 
Chugai Pharmaceutical Co Ltd (CUP) under the Base Case is 41 EUR per share.
Compared with the current market price of 38 EUR, the stock appears
Undervalued by 7% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Chugai Pharmaceutical Does
Chugai Pharmaceutical is a Japanese drug company that discovers, develops, manufactures, and sells prescription medicines. Its main products are treatments for cancer, immune diseases, blood disorders, bone and joint conditions, and other serious illnesses. The company is focused on medicines that doctors prescribe and hospitals use, not consumer health products.
- Headquarters
- Japan JP
- Employees
- 5 104
- IPO date
- Mar 3, 1956
Chugai Pharmaceutical has a narrow economic moat
Patent protection prevents rivals from freely copying Chugai’s medicines and the antibody technologies used to develop them. Drugs such as Hemlibra turn that protection into sales and licensing income, while its protected research technologies also support the development of new treatments.
Read the full moat analysis
Revenue & Expenses Breakdown
Chugai Pharmaceutical Co Ltd
Earnings Waterfall
Chugai Pharmaceutical Co Ltd
The intrinsic value for Chugai Pharmaceutical Co Ltd (CUP) under the Base Case is 41 EUR.
Compared with the current market price of 38 EUR, the stock appears Undervalued by 7% .